EXCLUSIVE: Trumps FDA nominee vows new abortion pill safety review after pressure from Sen Hawley

FIRST ON FOX: Food and Drug Administration (FDA) commissioner nominee Dr.Heidi Overton has committed to establishing a binding timeline and clear parameters for a safety study on the abortion medication mifepristone, the office of Sen.
Josh Hawley, R-Mo., told Fox News Digital on Friday.Hawley, a member of the Senate Health, Education, Labor and Pensions (HELP) Committee, has spent months pressing federal health officials for accountability over the delayed assessment."These are major pro-life wins that help ensure a robust study and the potential reinstatement of critical safeguards on the abortion drug that President Biden stripped away," Hawley said in a statement to Fox News Digital."I will expect that the FDA will live up to these promises, and as a member of the HELP Committee, any future FDA commissioner nominee must commit to carrying this through in order to earn my support."TRUMP TO NOMINATE DR HEIDI OVERTON AS NEXT FDA COMMISSIONERSen.
Senator Josh Hawley, R-Mo., who sits on the Senate Health, Education, Labor, and Pensions Committee said he has secured commitments from Food and Drug Administration (FDA) commissioner nominee Dr.Heidi Overton to establishing a binding timeline and data parameters for a safety study on the abortion medication mifepristone.
(Evelyn Hockstein/Reuters; Tom Williams-Pool/Getty Images)According to Hawley's office, the Trump administration has pledged to finalize a comprehensive mifepristone safety study by March 2027, with the FDA committing to enact regulatory changes supported by the findings no later than September 2027.Updated safety protocols would apply to both brand-name mifepristone and its generic equivalents.FEDERAL APPEALS COURT BLOCKS MAILING OF ABORTION PILLS IN RULING WITH NATIONWIDE EFFECTSenator Josh Hawley, a Republican from Missouri, arrives for a Senate Health, Education, Labor, and Pensions Committee confirmation hearing in Washington, DC, US, on Thursday, Sept.24, 2026.
(Daniel Heuer/Bloomberg via Getty ...